REGENERON PHARMACEUTICAInsider Trading & SEC Form 4 Analysis
Institutional analysis of internal capital flows based on SEC Form 4 filings.
Automated_Intelligence_Report :: REGN
Algorithmic analysis of recent insider trading activity for REGN reveals a bearish posture among the C-suite and board members. Based on the latest SEC Form 4 filings, we have tracked capital events executed by 17 distinct corporate insiders. The aggregate nominal exposure during this reporting cycle reached $447.39M.
Market dynamics show a negative net capital flow of $4.37M when isolating open-market purchases versus open-market sales. Interestingly, a significant portion of the total volume is driven by the exercise of options or grants rather than open-market transactions, suggesting that insiders are currently prioritizing compensation-based equity accumulation or tax-related liquidation over voluntary portfolio rebalancing.
From a microstructural perspective, the most significant liquidity event was a divestment by Bassler Bonnie L (Director), which accounts for a major share of the recent outflow. Continuous monitoring of these Tier-1 actors is essential, as their liquidity decisions often precede material corporate events or reflect an informed, asymmetric perspective on the future performance of REGN.
$447.39M
USD NOMINAL VALUE17
UNIQUE C-SUITE ENTITIES2026.05.01
ISO_8601 FORMATAutomated_Queries :: Frequently Asked Questions
>Who is currently buying REGN stock?
Our algorithmic tracking of SEC Form 4 filings indicates no significant open-market buying activity by major executives for REGN in the recent reporting period.
>Are REGN insiders selling their shares?
Yes, we have tracked $4.37M in recent insider liquidations. The most notable recent seller is Bassler Bonnie L, who executed the largest single offload.
>What is the overall insider sentiment for REGN?
The short-term structural capital flow indicates a BEARISH sentiment, with a net flow of $4.37M generated by 17 active C-Suite entities.